Meeting
2017 ASCO Annual Meeting
Patterns of histologic response to neoadjuvant targeted therapy in patients with BRAF mutant melanoma.
Authors
Zeynep Eroglu
Moffitt Cancer Center, Tampa, FL
Zeynep Eroglu , Nikhil I. Khushalani , Jeani Rich , Amod Sarnaik , Jonathan S. Zager , Joseph Markowitz , Andrew Scott Brohl , Vernon K. Sondak , Jane Messina
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Melanoma/Skin Cancers
Track
Melanoma/Skin Cancers
Sub Track
Local-Regional Disease
Citation
J Clin Oncol 35, 2017 (suppl; abstr 9584)
DOI
10.1200/JCO.2017.35.15_suppl.9584
Abstract #
9584
Poster Bd #
192
Abstract Disclosures
Similar Posters
Poster
2021 ASCO Annual Meeting
Outcomes of BRAF mutant metastatic melanoma (MM) patients (pts) after cessation of targeted therapy (TT) with BRAF or BRAF/MEK inhibitor(i).
First Author: Natalie Jackson
Poster
2021 ASCO Annual Meeting
Multicenter phase I/II trial of encorafenib with and without binimetinib in combination with nivolumab and low-dose ipilimumab in metastatic BRAF-mutant melanoma.
First Author: Max Jameson-Lee
Poster
2019 ASCO Annual Meeting
Molecular biology and treatment strategies for non-V600 BRAF-mutant NSCLC.
First Author: Marcelo Vailati Negrao
![SECOMBIT (sequential combo immuno and target therapy study): A three arms prospective, randomized phase II study to evaluate the best sequential approach with combo immunotherapy [ipilimumab (I) /nivolumab (N)] and combo target therapy [encorafenib (E)/binimetinib (B)] in patients with metastatic melanoma and BRAF mutation.](https://d201v5jt9ylckg.cloudfront.net/199/11950/153326/153326_poster_pv.jpg)
First Author: Paolo Antonio Ascierto